Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,500 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 July 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 205 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 97 results:
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is V  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
S. I. Vuik, Fontana, G., Mayer, E., and Darzi, A., “Do hospitalisations for ambulatory care sensitive conditions reflect low access to primary care? An observational cohort study of primary care usage prior to hospitalisation”, BMJ Open, vol. 7, p. e015704, 2017.
J. Voorham, Roche, N., Benhaddi, H., van der Tol, M., Carter, V., van Boven, J. F. M., Bjermer, L., Miravitlles, M., and Price, D. B., “Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK”, BMJ Open, vol. 8, p. e022051, 2018.
C. F. Vogelmeier, Kostikas, K., Fang, J., Tian, H., Jones, B., Morgan, C. L., Fogel, R., Gutzwiller, F. S., and Cao, H., “Evaluation of exacerbations and blood eosinophils in UK and US COPD populations”, Respir Res, vol. 20, p. 178, 2019.
A. Viswanathan, Spera, C., Mullins, A., Covert, D., Banhazi, J., McDwyer, P., Hudson, E., and Ferreira, A., “Resource Utilization Among Glaucoma Patients in the UK Treated with Beta-Blocker and Non-Beta-Blocker Adjunctive Therapy: A Retrospective Cohort Analysis”, Adv Ther, vol. 34, pp. 1695-1706, 2017.
P. A. Vissers, Cardwell, C. R., van de Poll-Franse, L. V., Young, I. S., Pouwer, F., and Murray, L. J., “The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes”, Breast Cancer Res Treat, vol. 150, pp. 427-37, 2015.
M. Violato, Gray, A., Papanicolas, I., and Ouellet, M., “Resource use and costs associated with coeliac disease before and after diagnosis in 3,646 cases: results of a UK primary care database analysis”, PLoS One, vol. 7, p. e41308, 2012.
Y. Vinogradova, Coupland, C., Hill, T., and Hippisley-Cox, J., “Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care”, Bmj, vol. 362, p. k2505, 2018.
Y. Vinogradova, Coupland, C., Brindle, P., and Hippisley-Cox, J., “Patients who discontinued statin treatment: a protocol for cohort study using primary care data”, BMJ Open, vol. 5, p. e008701, 2015.
Y. Vinogradova, Coupland, C., and Hippisley-Cox, J., “Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases”, Bmj, vol. 350, p. h2135, 2015.
Y. Vinogradova, Coupland, C., and Hippisley-Cox, J., “Exposure to combined oral contraceptives and risk of venous thromboembolism: a protocol for nested case-control studies using the QResearch and the CPRD databases”, BMJ Open, vol. 4, p. e004499, 2014.
Y. Vinogradova, Coupland, C., and Hippisley-Cox, J., “Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases”, Br J Cancer, vol. 109, pp. 795-806, 2013.
Y. Vinogradova, Coupland, C., and Hippisley-Cox, J., “Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data”, Bmj, vol. 346, p. f114, 2013.
Y. Vinogradova, Coupland, C., and Hippisley-Cox, J., “Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases”, Bmj, vol. 364, p. k4810, 2019.
P. Vezyridis and Timmons, S., “Evolution of primary care databases in UK: a scientometric analysis of research output”, BMJ Open, vol. 6, p. e012785, 2016.
T. Verstraeten, Cattaert, T., Harris, J., Lopman, B., Tam, C. C., and Ferreira, G., “Estimating the Burden of Medically Attended Norovirus Gastroenteritis: Modeling Linked Primary Care and Hospitalization Datasets”, J Infect Dis, vol. 216, pp. 957-965, 2017.
T. Verstraeten, Cattaert, T., and Ferreira, G., “Gender inequality in acute gastro-enteritis rates in England.”, Value in Health, vol. 20, p. A781, 2017.
B. P. Verhaegh, de Vries, F., Masclee, A. A., Keshavarzian, A., de Boer, A., Souverein, P. C., Pierik, M. J., and Jonkers, D. M., “High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors”, Aliment Pharmacol Ther, vol. 43, pp. 1004-13, 2016.
B. M. Verdel, Souverein, P. C., Egberts, A. C., and Leufkens, H. G., “Difference in risks of allergic reaction to sulfonamide drugs based on chemical structure”, Ann Pharmacother, vol. 40, pp. 1040-6, 2006.
S. Venkatesan, Myles, P. R., McCann, G., Kousoulis, A. A., Hashmi, M., Belatri, R., Boyle, E., Barcroft, A., van Staa, T. P., Kirkham, J. J., Van Tam, J. S. Nguyen, Williams, T. J., and Semple, M. G., “Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study”, Health Technol Assess, vol. 19, pp. 1-132, 2015.
S. Venkatesan, Myles, P. R., Manning, H. J., Mozid, A. M., Andersson, C., Jorgensen, M. E., Hardman, J. G., Moonesinghe, S. R., Foex, P., Mythen, M., Grocott, M. P. W., and Sanders, R. D., “Cohort study of preoperative blood pressure and risk of 30-day mortality after elective non-cardiac surgery”, Br J Anaesth, vol. 119, pp. 65-77, 2017.
S. Venkatesan, Okoli, G. N., Mozid, A. M., Pickworth, T. W., Grocott, M. P., Sanders, R. D., and Myles, P., “Effects of five preoperative cardiovascular drugs on mortality after coronary artery bypass surgery: A retrospective analysis of an observational study of 16, 192 patients”, Eur J Anaesthesiol, vol. 33, pp. 49-57, 2016.
S. Venkatesan, Jorgensen, M. E., Manning, H. J., Andersson, C., Mozid, A. M., Coburn, M., Moonesinghe, S. R., Foex, P., Mythen, M., Grocott, M. P. W., Hardman, J. G., Myles, P. R., and Sanders, R. D., “Preoperative chronic beta-blocker prescription in elderly patients as a risk factor for postoperative mortality stratified by preoperative blood pressure: a cohort study”, Br J Anaesth, 2019.
L. R. Vaz, Jones, M. J., Szatkowski, L., Tata, L. J., Petrou, S., and Coleman, T., “Estimating the health-care costs of children born to pregnant smokers in England: cohort study using primary and secondary health-care data”, Addiction, vol. 113, pp. 1305-1316, 2018.
J. Vavanikunnel, Charlier, S., Becker, C., Schneider, C., Jick, S. S., Meier, C. R., and Meier, C., “Association between glycemic control and risk of fracture in diabetic patients: A nested case-control study”, J Clin Endocrinol Metab, 2019.
C. Vasilakis-Scaramozza and Jick, H., “Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives”, Lancet, vol. 358, pp. 1427-9, 2001.
C. Vasilakis-Scaramozza, Aschengrau, A., Cabral, H., and Jick, S. S., “Antidepressant use during early pregnancy and the risk of congenital anomalies”, Pharmacotherapy, vol. 33, pp. 693-700, 2013.
C. Vasilakis-Scaramozza, Aschengrau, A., Cabral, H. J., and Jick, S. S., “Antihypertensive drugs and the risk of congenital anomalies”, Pharmacotherapy, vol. 33, pp. 476-82, 2013.
C. Vasilakis-Scaramozza, Aschengrau, A., Cabral, H. J., and Jick, S. S., “Asthma drugs and the risk of congenital anomalies”, Pharmacotherapy, vol. 33, pp. 363-8, 2013.
C. Vasilakis, Jick, H., and M. Melero-Montes, delMar, “Risk of idiopathic venous thromboembolism in users of progestagens alone”, Lancet, vol. 354, pp. 1610-1, 1999.
C. Vasilakis, Jick, S. S., and Jick, H., “The risk of venous thromboembolism in users of postcoital contraceptive pills”, Contraception, vol. 59, pp. 79-83, 1999.
F. K. Varyani, West, J., and Card, T. R., “An increased risk of urinary tract infection precedes development of primary biliary cirrhosis”, BMC Gastroenterol, vol. 11, p. 95, 2011.
F. K. Varyani, West, J., and Card, T. R., “Primary biliary cirrhosis does not increase the risk of UTIs following diagnosis compared to other chronic liver diseases?”, Liver Int, vol. 33, pp. 384-8, 2013.
S. J. Varney and Guest, J. F., “Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK”, Pharmacoeconomics, vol. 22, pp. 1141-51, 2004.
C. Varas-Lorenzo, Arana, A., Johannes, C. B., McQuay, L. J., Rothman, K. J., and Fife, D., “Improving the Identification of Out-of-Hospital Sudden Cardiac Deaths in a General Practice Research Database”, Drugs Real World Outcomes, vol. 3, pp. 353-358, 2016.
C. Varas-Lorenzo, Garcia-Rodriguez, L. A., Perez-Gutthann, S., and Duque-Oliart, A., “Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study”, Circulation, vol. 101, pp. 2572-8, 2000.
S. Vanni, Zattoni, M., Moda, F., Giaccone, G., Tagliavini, F., Haik, S., Deslys, J. P., Zanusso, G., Ironside, J. W., Carmona, M., Ferrer, I., Kovacs, G. G., and Legname, G., “Hemoglobin mRNA Changes in the Frontal Cortex of Patients with Neurodegenerative Diseases”, Front Neurosci, vol. 12, p. 8, 2018.
A. M. van Strien, Souverein, P. C., Keijsers, C., Heerdink, E. R., Derijks, H. J., and van Marum, R. J., “Association Between Urinary Tract Infections and Antipsychotic Drug Use in Older Adults”, J Clin Psychopharmacol, vol. 38, pp. 296-301, 2018.
T. Van Staa, Abenhaim, L., and Cooper, C., “Upper gastrointestinal adverse events and cyclical etidronate”, Am J Med, vol. 103, pp. 462-7, 1997.
T. Van Staa, Abenhaim, L., and Monette, J., “Rates of hypoglycemia in users of sulfonylureas”, J Clin Epidemiol, vol. 50, pp. 735-41, 1997.
T. P. van Staa, Leufkens, H. G., Zhang, B., and Smeeth, L., “A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example”, PLoS Med, vol. 6, p. e1000194, 2009.
T. P. van Staa and Sprafka, J. M., “Study of adverse outcomes in women using testosterone therapy”, Maturitas, vol. 62, pp. 76-80, 2009.
T. P. van Staa, Geusens, P., Zhang, B., Leufkens, H. G., Boonen, A., and Cooper, C., “Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids”, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
T. P. van Staa, Cooper, C., Barlow, D., and Leufkens, H. G., “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
T. P. van Staa, Rietbrock, S., Setakis, E., and Leufkens, H. G., “Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?”, J Intern Med, vol. 264, pp. 481-92, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., “Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., “What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Does a fracture at one site predict later fractures at other sites? A British cohort study”, Osteoporos Int, vol. 13, pp. 624-9, 2002.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
T. P. van Staa, Selby, P., Leufkens, H. G., Lyles, K., Sprafka, J. M., and Cooper, C., “Incidence and natural history of Paget's disease of bone in England and Wales”, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
T. P. van Staa, Boulton, F., Cooper, C., Hagenbeek, A., Inskip, H., and Leufkens, H. G., “Neutropenia and agranulocytosis in England and Wales: incidence and risk factors”, Am J Hematol, vol. 72, pp. 248-54, 2003.
[Page last reviewed 6 July 2020]